- Home
- /
- Treatment
- /
- Page 68
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide | Diagnostic for the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumors | Advanced Accelerator Applications;20 Rue Diesel, 01630;Saint Genis Pouilly | December 31, 2013 | |
NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)] | Leakage from the surgical site following penetrating keratoplasty | US Biotest, Inc.;231 Bonetti Dr.,, Suite 240;San Luis Obispo, California, 93401 | December 31, 2013 | |
N-acetyl cysteine amide | Retinitis pigmentosa | Nacuity Pharmaceuticals, Inc.;Fort Worth Club Building, 306 W 17th Street;Fort Worth, Texas, 76106 | December 31, 2013 | |
Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide | Diagnostic for the clinical management of neuroendocrine tumors | Advanced Accelerator Applications, USA;350 Fifth Avenue, Suite 6902;New York, New York, 10118 | December 31, 2013 | |
Tolcapone | Hereditary ATTR amyloidosis | Corino Therapeutics, Inc.;57 West 57th Street, 18th Floor;New York, New York, 10019 | December 24, 2013 | |
Erdosteine | Bronchiectasis | Alitair Pharmaceuticals, Inc.;55 Madison Avenue, Suite 400;Morristown, New Jersey, 07960 | December 20, 2013 | |
Tacrolimus | Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant | Veloxis Pharmaceuticals, Inc.;499 Thornall Street, 3rd Floor;Edison, NJ, 08837 | December 20, 2013 | |
CD40/CD80/CD86 modified autologous dendritic cell therapy | Treatment Type 1 diabetes mellitus patients with residual beta cell function | DiaVacs, Inc.;410 Tower Drive;Edgewater, New Jersey, 07020 | December 20, 2013 | |
Fenfluramine HCI | Dravet Syndrome | Zogenix, Inc.;5858 Horton Street, Suite 455, RG9 2LT;Emeryville, California | December 20, 2013 | |
Tacrolimus | Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant | Veloxis Pharmaceuticals, Inc.;499 Thornall Street, 3rd Floor;Edison, New Jersey, 08837 | December 20, 2013 | |
Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2) | Prevention (inhibition) of complement-mediated thrombotic microangiopathy | Omeros Corporation;201 Elliott Avenue West;Seattle, Washington, 98119 | December 16, 2013 | |
Marizomib | Multiple myeloma | Triphase Research and Development I Corp.;3210 Merryfield Row;San Diego, CA, 92121 | December 13, 2013 | |
O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate | Multiple myeloma | JSK Therapeutics, Inc.;85 Fort Douglas Boulevard, P.O. Box 58986;Salt Lake City, Utah, 84158 | December 13, 2013 | |
Marizomib | Multiple myeloma | Triphase Research & Development I Corp.;3366 N. Torrey Pines Court, Suite 210;La Jolla, California, 92037 | December 13, 2013 | |
Canakinumab | Familial Mediterranean fever | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 | December 5, 2013 | |
Canakinumab | Hyper-IgD syndrome | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 | December 5, 2013 | |
Sacituzumab govitecan | Small cell lung cancer | Immunomedics, Inc.;300 The American Road;Morris Plains, New Jersey, 07950 | November 27, 2013 | |
N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate | Gliomas | Kinex Pharmaceuticals, Inc.;701 Ellicott Street;Buffalo, New York, 14203 | November 26, 2013 | |
Bendamustine hydrochloride | Follicular lymphoma | Cephalon, Inc.;A wholly owned subsidiary of Teva Pharmaceuticals, PO Box 4011;Frazer, Pennsylvania, 19355 | November 26, 2013 | |
Siponimod | Polymyositis | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 | November 26, 2013 | |
Angiotensin (1-7) | Limb-girdle muscular dystrophy | Tarix Pharmaceuticals Ltd;12 Bow Street;Cambridge, Massachusetts, 02138 | November 26, 2013 | |
Adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene | Leber Hereditary Optic Neuropathy | Gen Sight Biologics;; | November 20, 2013 | |
Filgrastim | Subjects at risk of developing myelosuppression after a radiological or nuclear incident | Amgen, Inc.;One Amgen Center Drive, M/S 17-1-C;Thousand Oaks, California, 91320 | November 20, 2013 | |
Pegfilgrastim | Subjects at risk of developing myelosuppression after a radiological or nuclear incident | Amgen, Inc.;One Amgen Center Drive, M/S 17-1-C;Thousand Oaks, California, 91320 | November 20, 2013 | |
Emricasan | Liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease | Conatus Pharmaceuticals Inc.;16745 W. Bernardo Drive, Suite 200;San Diego, California, 92127 | November 20, 2013 |